

# COVID-19 boosters provide better immunity against SARS-CoV-2 variants in elderly Singaporeans

October 12 2022

---



Understanding the impact of age on vaccinations is essential for the design and delivery of safe vaccines against SARS-CoV-2 (Image: A\*STAR ID Labs).  
Credit: A\*STAR ID Labs

Elderly Singaporeans who are above 60 years old develop weaker vaccine-acquired immunity against COVID-19 upon receiving two doses of the Pfizer/BioNTech BNT162b2 vaccine, in comparison to their younger counterparts. These findings are from a new study led by researchers from the A\*STAR Infectious Diseases Labs (ID Labs). The study, published online in *Nature Communications*, also demonstrates that a third vaccine dose, or booster jab, alleviates the weak immune response observed in the elderly by increasing the levels of virus-specific antibodies and T cell responses against the ancestral SARS-CoV-2 Wuhan strain, the delta and omicron variants.

The study involved the participation of 312 individuals, including [health care workers](#) and [elderly individuals](#), who received a primary COVID-19 vaccination regime consisting of two doses of Pfizer/BioNTech BNT162b2 SARS-CoV-2 mRNA vaccine. Researchers conducted a comprehensive analysis of different immune parameters such as SARS-CoV-2-specific antibodies, memory B cell levels and virus-specific T cell responses, to assess the establishment and persistence of vaccine-acquired immunity. It is widely accepted that high antibody and memory B cell levels are essential for protection against infection while strong T cell responses protect against [severe disease](#).

The study revealed that upon the two-dose regime, most vaccinees developed robust antibody, B and T cell responses against the ancestral SARS-CoV-2 Wuhan strain. However, vaccine-induced immunity against the [delta](#) and omicron variants was less effective, suggesting the possibility of breakthrough infections. Waning of the antibody and cellular responses was also observed in 30% of the participants after 6 months from their second dose.

Importantly, researchers observed that individuals older than 60 years displayed weaker virus-specific antibody responses than younger Singaporeans (

Citation: COVID-19 boosters provide better immunity against SARS-CoV-2 variants in elderly Singaporeans (2022, October 12) retrieved 27 December 2022 from <https://medicalxpress.com/news/2022-10-covid-boosters-immunity-sars-cov-variants.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.